Steroid-free living donor liver transplantation in adults: Impact on hepatitis C recurrence

Clinical Transplantation

Volumn 23, Issue 6, 2009, Pages 904-913

  Marubashi, Shigeru ^a   Dono, Keizo ^a   Nagano, Hiroaki ^a   Kim, Chiwan ^a   Asaoka, Tadafumi ^a   Hama, Naoki ^a   Kobayashi, Shogo ^a   Takeda, Yutaka ^a   Umeshita, Koji ^a   Monden, Morito ^a   Doki, Yuichiro ^a   Mori, Masaki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatitis C recurrence; Live donor transplantation; Risk factors; Steroid free immunosuppressive regimens

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PREDNISOLONE; RIBAVIRIN; STEROID; TACROLIMUS; VIRUS RNA; HEPATITIS C ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; INCIDENCE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; PRIORITY JOURNAL; RECURRENCE RISK; COMPARATIVE STUDY; COMPLICATION; CONTRAINDICATIONS; FOLLOW UP; GRAFT REJECTION; HEPACIVIRUS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; SECONDARY PREVENTION; TREATMENT OUTCOME; VIROLOGY;

ADULT; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SECONDARY PREVENTION; STEROIDS; TREATMENT OUTCOME;

EID: 71149099685     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01022.x     Document Type: Article

References (41)

1. Berenguer M, Ferrell L, Watson J. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000, 32:673.
2. Berenguer M, Prieto M, Rayon JM. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000, 32:852.
3. Martin P, Busuttil RW, Goldstein RM. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004, 10:1258.
4. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122:889.
5. Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat 2007, 14:89.
6. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003, 9:S63.
7. McCaughan GW, Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 2004, 40:368.
8. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539.
9. Marubashi S, Dono K, Amano K. Steroid-free living-donor liver transplantation in adults. Transplantation 2005, 80:704.
10. Tisone G, Angelico M, Palmieri G. Immunosuppression without prednisone after liver transplantation is safe and associated with normal early graft function: preliminary results of a randomized study. Transpl Int 1998, 11:S267.
11. Margarit C, Bilbao I, Castells L. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int 2005, 18:1336.
12. Kato T, Gaynor JJ, Yoshida H. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007, 84:829.
13. Klintmalm GB, Washburn WK, Rudich SM. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007, 13:1521.
14. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000, 32:1125.
15. Gane EJ, Naoumov NV, Qian KP. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996, 110:167.
16. Nelson DR, Soldevila-Pico C, Reed A. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001, 7:1064.
17. Feray C, Gigou M, Samuel D. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995, 108:1088.
18. Charlton M, Seaberg E, Wiesner R. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998, 28:823.
19. Berenguer M, Prieto M, San Juan F. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002, 36:202.
20. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002, 51:248.
21. Rifai K, Sebagh M, Karam V. Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. J Hepatol 2004, 41:446.
22. Pelletier SJ, Raymond DP, Crabtree TD. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. Hepatology 2000, 32:418.
23. Sheiner PA, Schwartz ME, Mor E. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995, 21:30.
24. Prieto M, Berenguer M, Rayon JM. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999, 29:250.
25. Berenguer M, Crippin J, Gish R. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003, 38:34.
26. Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl 2001, 7:693.
27. Filipponi F, Salizzoni M, Grazi G, Pisati R, Ferrara R. Study of simulect-based, steroid-free immunosuppressive regimen in HCV+ de novo liver transplant patients: preliminary results. Transplant Proc 2001, 33:3211.
28. Eason JD, Blazek J, Mason A, Nair S, Loss GE. Steroid-free immunosuppression through thymoglobulin induction in liver transplantation. Transplant Proc 2001, 33:1470.
29. Ringe B, Braun F, Schutz E. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001, 71:508.
30. Figueras J, Bernardos A, Prieto M. Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients. Transplant Proc 2002, 34:1511.
31. Langrehr JM, Neumann UP, Lang M. First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. Transplant Proc 2002, 34:1565.
32. Pirenne J, Aerts R, Koshiba T. Steroid-free immunosuppression during and after liver transplantation--a 3-yr follow-up report. Clin Transplant 2003, 17:177.
33. Reding R, Gras J, Sokal E, Otte JB, Davies HF. Steroid-free liver transplantation in children. Lancet 2003, 362:2068.
34. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003, 75:1396.
35. Liu CL, Fan ST, Lo CM. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl 2004, 10:728.
36. Filipponi F, Callea F, Salizzoni M. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004, 78:1488.
37. Reggiani P, Arru M, Regazzi M. A " steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation. Transplant Proc 2005, 37:1697.
38. Pelletier SJ, Vanderwall K, Debroy MA. Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation. Transplant Proc 2005, 37:1214.
39. Boillot O, Mayer DA, Boudjema K. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005, 11:61.
40. Llado L, Xiol X, Figueras J. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol 2006, 44:710.
41. Nair S, Loss GE, Cohen AJ, Eason JD. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation 2006, 81:620.